Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Genetic Counseling for Patients with Non-Clear Cell RCC

April 26th 2023

The panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.

Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

April 26th 2023

The panel discusses the best approaches to treating patients with non-clear cell RCC.

TRAVERSE Study Shows Preliminary Efficacy and Safety of ALLO-316 in Advanced Clear Cell RCC

April 25th 2023

Samer A. Srour, MB ChB, MS, explains the unique construction of ALLO-316, the potential for ALLO-316 to address an unmet need in patients with clear cell renal cell carcinoma, and how early data from the TRAVERSE study support the continued investigation of ALLO-316 in patients with CD70-expressing tumors.

Batiraxcept Plus Cabozantinib Has Tolerable Safety Profile in Metastatic Clear Cell RCC

April 21st 2023

The combination of batiraxcept and cabozantinib is safe and generated early evidence of efficacy in pretreated patients with advanced or metastatic clear cell renal cell carcinoma.

Post-Hoc Analysis Supports Adjuvant Pembrolizumab in ccRCC at Increased Risk of Recurrence

April 19th 2023

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis–free survival vs placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, irrespective of UCLA Integrated Staging System risk category and disease stage.

Preferred Treatment Regimens for Refractory RCC

April 19th 2023

The panel shares their preferred treatment regimens for patients with refractory renal cell carcinoma.

Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC

April 19th 2023

Hans Hammers, MD, presents a profile of a 47-year-old male with refractory renal cell carcinoma.

ALLO-316 Demonstrates Antitumor Activity in Advanced Clear Cell RCC

April 17th 2023

The allogeneic anti-CD70 CAR T-cell therapy ALLO-316 elicited signals of antitumor activity and showed a tolerable safety profile in patients with advanced or metastatic clear cell renal cell carcinoma.

Dr Srour on the Phase 1 TRAVERSE Study of ALLO-316 in Metastatic Clear Cell RCC

April 17th 2023

Samer A. Srour, MB, ChB, MS, discusses the study design of the phase 1 TRAVERSE study, and key data on the use of ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.

Dr McGregor on Next Steps For Cabozantinib Plus Atezolizumab in Advanced RCC

April 14th 2023

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Clinical Pearls for Treating Advanced Renal Cell Carcinoma

April 14th 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, close their discussion with clinical pearls for community oncologists treating patients with advanced RCC.

Updates in the Adjuvant Treatment of Metastatic RCC

April 12th 2023

The panel discusses recent clinical trial data in the adjuvant treatment of metastatic renal cell carcinoma.

Dr Rini on Retreatment With Immunotherapy Following Progression in RCC

April 11th 2023

Brian I. Rini, MD, FASCO, discusses the investigation of immunotherapy following disease progression on previous immunotherapy in patients with relapsed/refractory renal cell carcinoma.

Dr Braun on Frontline Nivolumab Monotherapy Followed by Salvage Nivolumab/Ipilimumab in RCC

April 10th 2023

David A. Braun, MD, PhD, discusses the rationale for evaluating frontline nivolumab and salvage nivolumab plus ipilimumab in patients with advanced renal cell carcinoma in the phase 2 HCRN GU16-260 trial.

Durvalumab Plus Guadecitabine Induces Responses in Checkpoint Inhibitor–Naïve ccRCC

April 10th 2023

The combination of durvalumab and guadecitabine generated early signs of clinical activity and tolerability in patients with advanced clear cell renal cell carcinoma, particularly those with no prior exposure to checkpoint inhibitors.

Dr Ryan on the Evolution of the Treatment Landscape in RCC

April 7th 2023

Christopher W. Ryan, MD, professor of medicine School of Medicine at the Oregon Health & Science University, discusses the evolution of therapeutic treatment approaches across the management treatment landscape of renal cell carcinoma.

Advanced RCC Treatments Following Prior Immune Checkpoint Inhibitors

April 7th 2023

Drs Barata and Garmezy give detailed thoughts on treating patients with advanced RCC who have received prior immune checkpoint inhibitors.

TIVO-3 Trial: Tivozanib for Patients With Advanced RCC

April 7th 2023

A comprehensive overview of the TIVO-3 trial, which compared tivozanib with sorafenib in patients with advanced renal cell carcinoma.

Dr Atkins on the Rationale of Investigating Nivolumab/Ipilimumab in RCC

April 6th 2023

Michael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

Dr Albigès on the Efficacy of Cabozantinib in Pretreated RCC

April 5th 2023

Laurence Albigès, MD, PhD, discusses on the safety and efficacy of cabozantinib in patients with unresectable, locally advanced or metastatic renal cell carcinoma with a clear cell component.